For GW Pharmaceuticals (NASDAQ: GWPH), the main growth strategy for the current fiscal year is to expand its product pipeline beyond Epidiolex,
Stock Analysis: GW Pharma (GWPH) offers irresistible upside potential
For GW Pharmaceuticals (NASDAQ: GWPH), the main growth strategy for the current fiscal year is to expand its product pipeline beyond Epidiolex,
-- Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a
-- BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of
-- AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019
-- Biotechnology company Amicus Therapeutics (NASDAQ: FOLD) reported a net loss of $356.4 million or $1.48 per share for fiscal 2019, compared
-- Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) reported its fourth-quarter 2019 adjusted earnings of $0.48 per share versus $0.46 per share expected. --
UnitedHealth Group (NYSE: UNH) reported better-than-expected earnings for the fourth quarter of 2019 while revenues matched estimates. Shares were down 0.40% in
UnitedHealth Group (NYSE: UNH) has been expanding its market value steadily, especially after reporting stronger-than-expected third-quarter results a few months ago. Since
Walgreens Boots Alliance Inc. (NASDAQ: WBA) reported a 25% drop in earnings for the first quarter of 2020 due to higher charges
Though Amarin Corporation (NASDAQ: AMRN) has been showing signs of recovery since last year, after staying low for several years, the stock
Walgreens Boots Alliance (NYSE: WBA) entered the new fiscal after a disappointing show last year, in terms of shareholder return and financial
Rite Aid Corporation (NYSE: RAD) stock soared to a yearly high of $20.38 on Friday as investors were positive about the company's
-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported earnings of 69 cents per share during fiscal year 2019, compared to a loss of
-- Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
-- Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected. -- Revenues fell 47% to approx.
-- Catalyst Pharmaceutical (NASDAQ: CPRX) reported third quarter 2019 earnings of $0.13 per share, vs. $0.11 per share expected. -- Net product
-- BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period. --
-- Humana Inc. (NYSE: HUM) reported third-quarter 2019 earnings of $5.03 per share, vs. $4.58 per share expected. -- Total revenue rose
-- Perrigo Company plc (NYSE: PRGO) reported Q3 2019 earnings of $1.04 per share, vs. $0.93 expected. -- Sales grew 5.1% to
Drugmaker Mylan (NASDAQ: MYL) reported third-quarter revenues that fell short of expectations. Meanwhile, earnings increased and surpassed the consensus estimate. The company
-- Endo International plc (NASDAQ: ENDP) reported Q3 2019 earnings of $0.60 per share, vs. $0.53 expected. -- Revenues fell 2% to